Publications Office of the EU
Aufhebung des Open house Verfahrens Arzneimittelrabattverträge Denosumab, ATC M05BX04 - EU tenders
DisplayCustomHeader
Procurement Detail Actions Portlet
OP Portal - Procurement - Details

Aufhebung des Open house Verfahrens Arzneimittelrabattverträge Denosumab, ATC M05BX04

  • Canceled
    16/05/2025
  • Today
    24/06/2025
Status
Canceled
Type of contract
Supplies
Subject for Renewal
No
Buyer
AOK Bayern - Die Gesundheitskasse
Place of performance
NUTS code: Multiple place of performance
Location of buyer
NUTS code: DE212 München, Kreisfreie Stadt
Business sector (Main CPV)
33600000 Pharmaceutical products
Total estimated contract value (excluding VAT)
Not available
Total final contract value (excluding VAT)
The procedure is closed
Tender reference number
25-057
Description

Das Open house Verfahren Arzneimittelrabattverträge Denosumab, ATC M05BX04 wird zum 30.06.2025 aufgehoben. Alle bestehenden Verträge werden zum 30.06.2025 gekündigt. Der Abschluss von Verträgen ist im Rahmen dieses Open House Verfahrens nicht mehr möglich.

Submission Method
Not available
Tenders may be submitted
Not available
Information about a public contract, a framework agreement or a dynamic purchasing system (DPS)
The procurement involves the establishment of a framework agreement
Conditions for opening tenders (date)
Not available
Award method
unpublished
Estimated value
Not available
Final contracted value
The procedure is closed
Award of contract
The procedure is closed
Prior information
Contract
Award
Footnote - legal notice

This content published on this page is meant purely as an additional service and has no legal effect. The Union's institutions do not assume any liability for its contents. The official versions of the relevant tendering notices are those published in the Supplement of Official Journal of the European Union and available in TED. Those official texts are directly accessible through the links embedded in this page. For more information please see Public Procurement Explainability and Liability notice.